GlassScriptPhysician profile
Annette Davis
NPI 1285720045
$3,161.50
in general payments reported to CMS, 2019-2025
34 companies · $675 in 2025
The $675 reported for 2025 was more than what 91% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $892 · 2023: $555 · 2024: $706 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.89 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $323.67 | 2021-2025 | |
| Astellas Pharma US INC | $314.69 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $241.95 | 2021-2025 | |
| Biogen, INC. | $226.38 | 2024-2025 | Zurzuvae |
| Csl Behring | $215.16 | 2021-2022 | |
| Shield Therapeutics INC | $211.27 | 2023-2024 | Accrufer |
| Exeltis, USA INC. | $205.17 | 2022-2025 | Slynd |
| Novo Nordisk INC | $133.91 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $119.70 | 2023 | Jemperli |
| Myovant Sciences INC. | $114.58 | 2022 | |
| Hologic Sales and Service, LLC | $109.13 | 2022-2025 | Novasure, Acessa Provu System, Aptima |
| Sumitomo Pharma America, INC. | $105.16 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $72.00 | 2022 | |
| Avion Pharmaceuticals | $66.83 | 2021-2023 | Balcoltra |
| Amgen INC. | $62.59 | 2021-2025 | Evenity, Prolia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $62.52 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.50 | 2023-2025 | Gardasil 9, Gardasil |
| Organon LLC | $50.68 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $48.13 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.10 | 2021-2023 | |
| Millicent US INC | $44.36 | 2025 | Intrarosa, Femlyv |
| Channel Medsystems, INC. | $36.34 | 2024 | |
| Exact Sciences Corporation | $34.69 | 2024-2025 | Cologuard Collection Kit |
| Pharmacosmos Therapeutics INC. | $33.26 | 2023-2024 | Monoferric |
| Biohaven Pharmaceutical Holding Company LTD. | $31.52 | 2022 | |
| Lilly USA, LLC | $29.58 | 2024 | Zepbound |
| Boston Scientific Corporation | $28.27 | 2025 | Bodyguardian |
| Scynexis, INC. | $27.05 | 2022 | |
| Evofem Biosciences, INC. | $23.54 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.20 | 2025 | |
| Daiichi Sankyo INC. | $18.99 | 2025 | Injectafer |
| Radius Health, INC. | $18.55 | 2025 | Tymlos |
| Pfizer INC. | $18.32 | 2025 | |
| Smith+Nephew, INC. | $13.71 | 2025 | Pico 7 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.